Peptide drugs offer high target affinity and specificity, but low bioavailability and poor stability can limit their therapeutic effectiveness. Optimizing DMPK properties is crucial to unlocking their full potential. Join WuXi AppTec and AAPS in today’s webinar to discover actionable strategies for enhancing peptide permeability, stability, and bioavailability. Learn how our in vitro models, tailored sample processing, and expert insights can accelerate your peptide drug development from early screening to IND submission. 🕒 Time: 11:15 AM - 11:45 AM EST, today 🔗 There’s still time to register: https://hubs.li/Q02Vn7XP0 (free to everyone, but you’ll need to register a free account at AAPS) #PeptideDrugs #DMPK #PharmaResearch #DrugDevelopment #Bioavailability #PharmaceuticalScience #INDSubmission
WuXi AppTec, Laboratory Testing Division
Pharmaceutical Manufacturing
Plainsboro, NJ 5,169 followers
Your success is our success.
About us
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated.“ Our state-of-the-art Laboratory Testing Division in New Jersey provides leading bioanalytical & drug metabolism contract research services to a global customer base of pharmaceutical, biotech & agrochemical firms. Our bioanalytical services support a wide range of compounds-small & large molecules, new modalities including oligonucleotides, ADC, bispecific antibodies & more-from discovery to preclinical IND-enabling & regulated clinical studies. Capabilities include LC-MS/MS & immunochemistry platforms for GLP & non-GLP & customized Central Laboratory services to facilitate global clinical studies. Our comprehensive drug metabolism services are tailored to support the entire drug development cycle, from early discovery through IND-enabling to late-stage clinical development. Capabilities include in vivo pharmacokinetics, in vitro ADME, in vitro & in vivo biotransformation, & non-clinical radiolabel ADME (mass balance & QWBA).
- Website
-
https://labtesting.wuxiapptec.com/
External link for WuXi AppTec, Laboratory Testing Division
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Plainsboro, NJ
- Type
- Public Company
- Founded
- 1987
- Specialties
- ADME, DMPK, bioanalysis, drug metabolism, animal health, and agrochemical
Locations
-
Primary
Get directions
107 Morgan Lane
Plainsboro, NJ 08536, US
-
Get directions
6 Cedar Brook Dr
Cranbury, NJ 08512, US
Employees at WuXi AppTec, Laboratory Testing Division
-
Virginia Pate Whitaker
Associate Director, Laboratory Operations at WuXi AppTec
-
Kristin Peterson
Director, Business Development, Western US Region and APAC at WuXi AppTec
-
Keith Ciccaglione
Scientist II at WuXi AppTec, Laboratory Testing Division, New Jersey site
-
TJ Sigler
Executive Director, Head of International Sales & Marketing | Laboratory Testing Division at WuXi AppTec
Updates
-
From Lab to Clinic: Ensuring the Safety of Oligonucleotide Drugs The unique properties of oligonucleotide drugs demand equally unique preclinical safety strategies. Our latest blog offers an overview for addressing these challenges, including: • Comprehensive safety assessments • Innovations in bioanalytical techniques like LC-MS/MS and qPCR • Managing immunotoxicity and immunogenicity risks Discover the methodologies shaping the future of ON drug development! https://hubs.li/Q02TTDxM0 #Oligonucleotides #PreclinicalSafety #DrugDevelopment #BioanalyticalMethods #Immunogenicity #PharmaInnovation
-
WuXi AppTec, Laboratory Testing Division reposted this
Facing low bioavailability and poor stability in your peptide drugs? Discover actionable strategies to optimize their DMPK properties for improved development outcomes. Join WuXi AppTec and AAPS for an exclusive webinar, where you'll gain the insights needed to enhance peptide permeability and stability. Accelerate your journey from screening to IND submission with proven DMPK strategies. 📅 Date: November 6, 2024 🕒 Time: 11:15 AM - 11:45 AM EST 🔗 Register here: https://hubs.li/Q02Vm_540 (free to everyone, but you’ll need to register a free account at AAPS) #PeptideDrugs #DMPK #PharmaResearch #DrugDevelopment #Bioavailability #PharmaceuticalScience #INDSubmission
-
-
Going to #ACT2024? Our experts will be there at booth 500 to discuss how we can help streamline your drug development program. Learn more about our capabilities and new imaging center. Be sure to attend our Exhibitor Hosted Session at the event: 📋 Maximizing Outcomes Through Multi-Site Study Collaboration 🎤 Sue McPherson, Executive Director, Toxicology, WuXi AppTec 🗓️ Tuesday, November 19th | 12:00 pm-12:55 pm 📍 Level 2, Room 203 Check out our two posters at the meeting and swing by booth 500 for our in-booth Gelato Bar on Monday from 5:00-6:00 pm 🍨 Get all the details here: https://hubs.li/Q02WtJk90 #ACT2024 #Toxicology #DrugDevelopment
-
-
Understanding suitable bioanalytical approaches is critical with the rapid development of mRNA-based treatments. Check out our on-demand webinar for a deep dive into the strategies and challenges in bioanalysis for LNP-mRNA products. https://hubs.ly/Q02TTvgd0
-
-
Traditional plasma protein binding (PPB) testing for oligonucleotides faces challenges, but Rapid Agarose Gel EMSA is here to make a difference. With its better accuracy and efficiency, it's not just an alternative but a potential standard for the future. Our recent research highlights its advantages, from cost savings to increased throughput. Find out how this advancement could lead to safer, more effective oligonucleotide drugs that reach patients sooner. https://hubs.li/Q02ShN670 #oligonucleotide #Biotech #DrugSafety #DrugDevelopment #RapidEMSA
Rapid EMSA: A New Method of Testing PPB in Oligonucleotides
https://labtesting.wuxiapptec.com
-
🎉 The 2024 Annual Meeting of the American College of Toxicology is just around the corner, and we’re thrilled to be a part of it! Join us in Austin, TX, and stop by Booth 500 to connect with the WuXi AppTec Lab Testing team. Don’t miss this chance to meet industry experts and learn how we can support your drug development efforts, including details on our new imaging center. Be sure to add our Exhibitor Hosted Session to your calendar: 📋 Maximizing Outcomes Through Multi-Site Study Collaboration 🎤 Sue McPherson, Executive Director, Toxicology, WuXi AppTec 🗓️ Tuesday, November 19th | 12:00 pm-12:55 pm 📍 Level 2, Room 203 Plus, look for our two informative poster presentations on the show floor, and treat yourself at our in-booth Gelato Bar on Monday from 5:00-6:00 pm. 🍦 Get more details here: https://hubs.li/Q02WtGsv0 #ACT2024 #Toxicology #DrugDevelopment
-
-
Facing low bioavailability and poor stability in your peptide drugs? Discover actionable strategies to optimize their DMPK properties for improved development outcomes. Join WuXi AppTec and AAPS for an exclusive webinar, where you'll gain the insights needed to enhance peptide permeability and stability. Accelerate your journey from screening to IND submission with proven DMPK strategies. 📅 Date: November 6, 2024 🕒 Time: 11:15 AM - 11:45 AM EST 🔗 Register here: https://hubs.li/Q02Vm_540 (free to everyone, but you’ll need to register a free account at AAPS) #PeptideDrugs #DMPK #PharmaResearch #DrugDevelopment #Bioavailability #PharmaceuticalScience #INDSubmission
-
-
WuXi AppTec’s team of researchers recently took a closer look at the FOB test, an important tool in determining neurotoxic effects. The findings will support safer drug development and provide a framework for future studies. Read more: https://hubs.li/Q02T1wYs0 #innovation #neurotoxicity #drugreseach
Understanding the Sensitivity and Accuracy of FOB Tests for CNS and non-CNS Targeted Compounds
-
Does your testing partner use automated liquid handling workstations? In vitro ADME testing automation provides three distinct advantages, accelerating your candidate's path to market. Learn more: https://hubs.li/Q02ShM6q0 #adme #dmpk #drugdevelopment #pharmaceuticals #innovation
3 Benefits of In Vitro ADME Testing Automation
https://labtesting.wuxiapptec.com